DMRA
NASDAQDamora Therapeutics Inc.
Price$21.34+1.01 (+4.97%)
02:15 PM07:45 PM
News · 26 weeks31-60%
2025-12-142026-06-07
Mix3190d
- Insider11(35%)
- SEC Filings8(26%)
- Analyst5(16%)
- Other4(13%)
- Leadership2(6%)
- Offering1(3%)
Latest news
25 items- ANALYSTH.C. Wainwright initiated coverage on Damora Therapeutics with a new price targetH.C. Wainwright initiated coverage of Damora Therapeutics with a rating of Buy and set a new price target of $45.00
- ANALYSTTD Cowen initiated coverage on Damora TherapeuticsTD Cowen initiated coverage of Damora Therapeutics with a rating of Buy
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora's common stock with a 10-yea
- ANALYSTWedbush initiated coverage on Damora Therapeutics with a new price targetWedbush initiated coverage of Damora Therapeutics with a rating of Outperform and set a new price target of $35.00
- SECSEC Form SCHEDULE 13G filed by Damora Therapeutics Inc.SCHEDULE 13G - Damora Therapeutics, Inc. (0001800315) (Subject)
- PRDamora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively – – Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-driven myeloproliferative neoplasms – – Strong financial position with approximately $533 million in cash and cash equivalents as of March 31, 2026, expected to fund operations in
- SECSEC Form 10-Q filed by Damora Therapeutics Inc.10-Q - Damora Therapeutics, Inc. (0001800315) (Filer)
- INSIDERSEC Form 3 filed by new insider Burkavage Brian3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SECDamora Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to two newly-hired, non-executive employees. The inducement grants were approved by Damora's independent Compensation Committee and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 57,500 shares of the Damora's common stock with a 10-year term and an exercise price of $25.66 p
- SECSEC Form DEFA14A filed by Damora Therapeutics Inc.DEFA14A - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form DEF 14A filed by Damora Therapeutics Inc.DEF 14A - Damora Therapeutics, Inc. (0001800315) (Filer)
- ANALYSTRBC Capital Mkts initiated coverage on Damora Therapeutics with a new price targetRBC Capital Mkts initiated coverage of Damora Therapeutics with a rating of Outperform and set a new price target of $40.00
- SECDamora Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
- INSIDERSEC Form 4 filed by Jarrett Jennifer4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jarrett Jennifer3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement grants were approved by Damora's Board of Directors or its independent Compensation Committee and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants made on March 24,
- INSIDERSEC Form 4 filed by Winslow Garrett4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Turtle Cameron4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Landsittel Michael4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Fairmount Funds Management Llc4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Cain Christopher W.4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 4 filed by Bruno Julianne4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Turtle Cameron3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Landsittel Michael3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
DMRA FAQ
6 questionsWhere does DMRA stock trade?
Damora Therapeutics Inc. (DMRA) is listed on NASDAQ.What sector and industry is DMRA in?
Damora Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Damora Therapeutics Inc. go public?
Damora Therapeutics Inc. (DMRA) completed its IPO in 2020.What are analysts saying about DMRA?
Damora Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $4500.00 price target on 2026-06-11. Recent price targets range from $3500.00 to $4600.00.What companies are similar to DMRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DMRA side-by-side with any of them on Quantisnow.How can I track DMRA on Quantisnow?
Quantisnow aggregates Damora Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DMRA to receive live email and push alerts on every new disclosure.